Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05440864
Title Durvalumab and Tremelimumab in Resectable HCC ((NEOTOMA))
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto
Age Groups: senior | adult
Covered Countries ITA | ESP | CAN

No variant requirements are available.